Dr Reddy’s Laboratories, Lupin Pharmaceuticals and Mylan Pharmaceuticals have successfully appealed against a New Jersey district court’s decision to uphold as valid two US patents protecting the Vimovo (naproxen/esomeprazole magnesium) combination marketed by Horizon Pharma under license from Nuvo.
The Court of Appeals for the Federal Circuit’s reversal of the lower court’s verdict adds to the New Jersey court’s finding in favor of Reddy’s and Mylan last year on US method-of-treatment patents 9,393,208 and 9,220,698 protecting Vimovo up to March 2031
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?